Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506):: Impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect

被引:38
作者
Härtel, C
Schumacher, N
Fricke, L
Ebel, B
Kirchner, H
Müller-Steinhardt, M
机构
[1] Med Univ Lubeck, Sch Med, Inst Immunol & Transfus Med, D-23538 Lubeck, Germany
[2] Med Univ Lubeck, Sch Med, Dept Pediat Med, D-23538 Lubeck, Germany
[3] Med Univ Lubeck, Sch Med, Dept Transplantat Med, D-23538 Lubeck, Germany
关键词
D O I
10.1373/clinchem.2003.024950
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: To optimize immunosuppressive treatment in individual transplant patients, functional measurements of the effects of tacrolimus (FK 506) are of clinical importance. Previous investigations have demonstrated the occurrence of tacrolimus-resistant production of interleukin-2 (IL-2) in vitro, which may explain in part why rejection episodes are still a frequent problem despite attainment of therapeutic blood concentrations and HLA matching. However, an adequate surrogate marker to define the tacrolimus response in individual patients has not been established. Methods: We investigated the immunosuppressive effects of tacrolimus on anti-CD3/anti-CD28 T-cell costimulation in a human whole-blood assay, analyzing T-cell proliferation, activation marker expression (CD25, CD69), IL-2 protein expression, and cytokine mRNA expression in vitro (n = 11 healthy individuals). We also quantified IL-2 mRNA expression in patients undergoing tacrolimus (n = 4) or cyclosporin A (CsA; n = 4) monotherapy before ex vivo living-donor kidney transplantation. Results: T-cell proliferation; CD25, CD69, and IL-2 concentrations; and IL-4 mRNA were significantly decreased in vitro. In contrast, cytokine mRNA profiles revealed variable tacrolimus sensitivity. Whole-blood samples from 3 of 11 healthy individuals demonstrated marked suppression of IL-2 mRNA expression (>50%) when tacrolimus was administered in vitro. When CsA was added to whole-blood cultures, the influence on IL-2 mRNA expression was comparable to that of tacrolimus in 9 of 11 individuals. Two individuals responded conversely, indicating that differences in the in vitro response to tacrolimus and CsA among individuals may be attributable to potential heterogeneity in the involvement of the CD28 pathway. Kinetic profiles of IL-2 mRNA expression also revealed individually distinct degrees of calcineurin inhibitor sensitivity in patients undergoing tacrolimus or CsA monotherapy before living-donor kidney transplantation. Conclusions: Our results suggest an individual degree of calcineurin inhibitor sensitivity of activated whole-blood lymphocytes based on IL-2 mRNA expression. Our approach is potentially valuable for identifying transplant patients in whom IL-2 mRNA expression is unaffected or even enhanced after initiation of immunosuppressive therapy. Such individuals may be less sensitive to the immunosuppressive agent and therefore at increased risk of transplant rejection. Prospective studies are necessary to determine the correlation of IL-2 mRNA expression with the clinical risk of transplant rejection. (C) 2004 American Association for Clinical Chemistry.
引用
收藏
页码:141 / 151
页数:11
相关论文
共 59 条
  • [1] The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system
    Anderson, DE
    Sharpe, AH
    Hafler, DA
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (06) : 677 - 683
  • [2] ANDERSSON J, 1992, IMMUNOLOGY, V75, P136
  • [3] CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression
    Appleman, LJ
    Berezovskaya, A
    Grass, I
    Boussiotis, VA
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (01) : 144 - 151
  • [4] New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
    Armstrong, VW
    Oellerich, M
    [J]. CLINICAL BIOCHEMISTRY, 2001, 34 (01) : 9 - 16
  • [5] Human T cell responses to human and procine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro
    Batten, P
    McCormack, AM
    Page, CS
    Yacoub, MH
    Rose, ML
    [J]. TRANSPLANTATION, 1999, 68 (10) : 1552 - 1560
  • [6] THE EFFECT OF THE IMMUNOSUPPRESSANT FK-506 ON ALTERNATE PATHWAYS OF T-CELL ACTIVATION
    BIERER, BE
    SCHREIBER, SL
    BURAKOFF, SJ
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (02) : 439 - 445
  • [7] NUCLEAR-ASSOCIATION OF A T-CELL TRANSCRIPTION FACTOR BLOCKED BY FK-506 AND CYCLOSPORINE-A
    FLANAGAN, WM
    CORTHESY, B
    BRAM, RJ
    CRABTREE, GR
    [J]. NATURE, 1991, 352 (6338) : 803 - 807
  • [8] Indications, results, and complications of tacrolimus conversion in pediatric renal transplantation
    Flynn, JT
    Bunchman, TE
    Sherbotie, JR
    [J]. PEDIATRIC TRANSPLANTATION, 2001, 5 (06) : 439 - 446
  • [9] EFFECTS OF CYCLOSPORINE-A, FK-506, AND MYCALAMIDE-A ON THE ACTIVATION OF MURINE-CD4+ T-CELLS BY THE MURINE B7-ANTIGEN
    GALVIN, F
    FREEMAN, GJ
    RAZIWOLF, Z
    BENACERRAF, B
    NADLER, L
    REISER, H
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (01) : 283 - 286
  • [10] Geginat J, 2000, EUR J IMMUNOL, V30, P1136, DOI 10.1002/(SICI)1521-4141(200004)30:4<1136::AID-IMMU1136>3.0.CO